Hematología y Hemoterapia

Resultados: 387
Tipo Título / Nombre Autor(es) Año
Lenalidomide plus R-GDP (R2-GDP) in relapsed/refractory diffuse large B-cell lymphoma: Final results of the R2-GDP-GOTEL trial Cruz Merino L de la, Martín A, Nogales Fernández E, Carnicero González F, Ríos Herranz E, Cruz Vicente F de la, et al 2020
Phase I/II study of avadomide (CC-122) in combination with R-CHOP for newly diagnosed DLBCL Mehta-Shah N, Chavez JC, Abrisqueta P, Johnson N, Bergua Burgues JM, Grande-García C, et al 2020
A phase Ib, Open-Labe, Randomized Study to Asses Safety and Preliminary Efficacy of Tafasitamab (MOR208) or Tafasitamab+ Lenalidomide in Addition to R-CHOP in Patients with Newly Diagnosed Diffuse Large B cell –lymphoma: Analysis of the Safety Run in Phase Belada D, Nowakowski GS, Bergua Burgués JM, André M, Kopeckova K, Stevens DA, et al 2020
Phase I/II study of avadomide (CC-122) in combination with R-CHOP for newly diagnosed DLBCL Martín A, Chavez J, Abrisqueta P, Johnson NA, Bergua Burgués JM, Grande-García C, et al 2020
Midostaurin in combination with intensive chemotherapy in patients iwth FLT3-mutated acute myeloid leukemia (AML). A real life multicenter experience from Spanish Tertiary Hospitals Tormo M, Díaz Beya M, Berneit P, Fernández A, Arnant M..., Bergua JM, et al 2020
Characteristics and treatment strategies of Secondary Acute Myeloid Leukemia Patients: Data from the PETHEMA AML epidemiological registry Martínez-Cuadrón D, Serrano J, Martínez O, Pérez-Simón JA, Gil C ..., Bergua JM, et al 2020
Bispecific T cell engager antibodies may contribute to reactivate pre-existing tumor specific T cells Primo D, Pérez Oteyza J, Bergua JM, Hernández Rivas JA, Ruiz E, Vives S, et al 2020
The mode of action (MOA) of the anti-CD38 monoclonal antibody (MAB) Isatuximab in elderly acute myeloid leukemia Zabaleta A, Alameda D, Ajona C, Perez C, Alignani D, ..., et al 2020
Corrigendum to "Performance of prognostic scoring systems in elderly patients with acute myeloid leukaemia on intensive chemotherapy: A PETHEMA registry study" [Leuk. Res. 92 (March) (2020) 106352] Rodríguez-Medina C, Martínez-Cuadrón D, Cano I, Gil C, Tormo M..., Bergua-Burgues JM, et al 2020
Lenalidomida + R-GDP (R2-GDP) en linfoma b difuso de células grandes refractario o en recaída. Resultados finales del ensayo R2-GDP-GOTEL Espejo García P, Martin García A, Palazón Carrión N, Nogales Fernández E, Carnicero González F, Rios Herranz E, et al 2020